Researchers say to conquer cancer you need to stop it before it becomes cancer

September 16, 2016, University of California - San Diego

In a Perspective piece published this week in PNAS, cancer researchers from across the country, including faculty at University of California San Diego School of Medicine and Moores Cancer Center, write that a greater emphasis on immune-based prevention should be central to new efforts like the federal Cancer Moonshot program, headed by Vice President Joe Biden.

"Science has devoted tremendous amounts of energy and resources to the treatment of , and in recent years, there has been significant progress. The cancer death rate has steadily declined for more than two decades," said Scott M. Lippman, MD, director of Moores Cancer Center and co-senior author of the PNAS paper. "But cancer still kills more than half a million Americans each year and afflicts many millions more. If we're ever to eradicate this scourge, we must work to prevent it from occurring altogether."

The authors, whose expertise encompasses immunology, genomics, epigenomics, computational biology, vaccines and medical genetics at institutions ranging from University of Washington and La Jolla Institute for Allergy and Immunology to the National Cancer Institute (NCI), Dana-Farber Cancer Institute and the Sidney Kimmel Comprehensive Cancer Center, say new research tools and other developments now make it possible to decipher in detail how different cancers begin, how benign or precancerous tissues turn malignant and deadly.

"Oncogenic transformation is a series of steps," said Elizabeth M. Jaffee, MD, co-senior author, co-chair of the Cancer Moonshot Blue Ribbon Panel and deputy director of the Kimmel Center at Johns Hopkins University School of Medicine. "The body's immune system is capable of intercepting pre-malignancies and preventing cancer. It does so countless times every day in all of us. That natural ability is what we want to leverage. Building upon our innate defenses against cancer is the foundation of new immunotherapies, which have shown great promise in a very short time."

But much more must be done, say the authors. Efforts like The Cancer Genome Atlas (TCGA) and genome-wide association studies (GWAS), which look for common genetic variants in different people to see if any variant is associated with a trait or, in this case, a cancer, have significantly advanced basic research in immune oncology and precision therapy. Both should be dramatically expanded to , the authors write.

Continued and new development of cancer vaccines will be critical, said Lippman, noting that the human papilloma virus (HPV) vaccine, co-developed by NCI Acting Director Douglas R. Lowy, MD, and co-author John Schiller, PhD, provides almost 100 percent protection against strains linked to several types of cancer.

Earlier this year, the Human Vaccines Project, a global public-private partnership of academic research centers, industry, non-profits and government agencies to accelerate development of next-generation vaccines and immunotherapies, announced that UC San Diego, with The Scripps Research Institute, J. Craig Venter Institute and La Jolla Institute for Allergy and Immunology, would serve as a hub for vaccine research.

The authors cited several cancers that were particularly ripe for immediate prevention efforts, including Lynch syndrome, an inherited condition that increases the risk of many cancers, including of the digestive and gynecologic tracts; clonal hematopoiesis, an age related precursor to leukemia; and cervical intraepithelial neoplasia, abnormal growth of cervix tissue caused by HPV that can progress to cervical cancer.

"Prevention research has made strides, but progress has been anecdotal and isolated," said Lippman. "If the goal is eradication of cancer, we need a radically new focus, investment and approach to premalignant diseases and cancer prevention, one that is supported and sustained by broad, deep efforts like the Cancer Moonshot and Human Vaccines Project."

Explore further: 10 Cancer Moonshot Blue Ribbon Panel recommendations embraced by NCI

More information: Preventive vaccines against precancerous lesions, PNAS,

Related Stories

10 Cancer Moonshot Blue Ribbon Panel recommendations embraced by NCI

September 7, 2016
When 28 distinguished individuals convened earlier this year to help shape the scientific mission at the National Cancer Institute (NCI) of Vice President Joe Biden's National Cancer Moonshot Initiative, they were given five ...

Report sets research priorities for Biden's cancer moonshot

September 8, 2016
A new report outlines a scientific roadmap for the White House's cancer "moonshot" initiative—urging research to harness the power of immune-based therapy, and to better tailor treatment by helping more patients get their ...

Cancer expert says public health and prevention measures are key to defeating cancer

March 3, 2016
Is investment in research to develop new treatments the best approach to controlling cancer? Would emphasizing prevention bring about more return on investment? Should we channel what we are learning about precision medicine ...

HPV-cancers on rise in United States

July 7, 2016
The number of cancers associated with the human papillomavirus (HPV) is on the rise in the United States, reaching nearly 39,000 each year, a US government report said Thursday.

CDC: Majority of HPV-linked cancers are preventable

July 11, 2016
(HealthDay)—The majority of cancers linked to human papillomavirus (HPV) are preventable, according to a report published in the July 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality ...

80 percent of cervical cancers found to be preventable with latest 9-valent HPV vaccine

May 11, 2015
The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.

Recommended for you

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.

Improved capture of cancer cells in blood could help track disease

March 15, 2018
Tumor cells circulating throughout the body in blood vessels have long been feared as harbingers of metastasizing cancer - even though most free-floating cancer cells will not go on to establish a new tumor.

Area surrounding a tumor impacts how breast cancer cells grow

March 14, 2018
Cancer is typically thought of as a tumor that needs to be removed or an area that needs to be treated with radiation or chemotherapy. As a physicist and cancer researcher, Joe Gray, Ph.D., thinks differently.

Obesity may promote resistance to antiangiogenic therapy for breast cancer

March 14, 2018
Obesity—which is already known to reduce survival in several types of cancer—may explain the ineffectiveness of angiogenesis inhibitors in the treatment of breast cancer. A research team led by Massachusetts General Hospital ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.